Trial Profile
A Phase II, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Reactogenicity and Immunogenicity of Three Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs RIX 4414 (Primary) ; Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix); Poliovirus vaccine live oral
- Indications Diphtheria; Pertussis; Poliomyelitis; Rotavirus infections; Tetanus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 23 Jun 2009 Additional trial centre identified as reported by ClinicalTrials.gov.
- 29 Jan 2008 Status change from recruiting to in progress, from clinicaltrials.gov record.
- 31 Oct 2006 New trial record.